Aptevo Therapeutics Inc (APVO)

$4.46 -0.05 (-1.11%)
Market Cap 2.30M
Revenue (ttm) 0.00
Net Income (ttm) -17.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 43,100
Avg Vol 244,386
Day's Range N/A - N/A
Shares Out 511,000.00
Stochastic %K 13%
Beta 5.11
Analysts Strong Sell
Price Target $21.00

Latest News on APVO

Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

Jan 15, 2025, 8:00 AM EST - 2 days ago

Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

Dec 12, 2024, 12:50 PM EST - 5 weeks ago

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

Dec 12, 2024, 9:00 AM EST - 5 weeks ago

100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects

Dec 4, 2024, 8:35 AM EST - 6 weeks ago

Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects

Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan

Nov 29, 2024, 9:55 AM EST - 7 weeks ago

Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan

Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation

Nov 26, 2024, 8:35 AM EST - 7 weeks ago

Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation

Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm

Nov 22, 2024, 8:35 AM EST - 2 months ago

Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm

First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies

Nov 20, 2024, 8:35 AM EST - 2 months ago

First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial

Nov 11, 2024, 8:15 AM EST - 2 months ago

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update

Nov 7, 2024, 8:05 AM EST - 2 months ago

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update

Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Sep 18, 2024, 4:05 PM EDT - 4 months ago

Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Sep 16, 2024, 8:05 PM EDT - 4 months ago

Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated

Aug 13, 2024, 8:05 AM EDT - 5 months ago

Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated

Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update

Aug 8, 2024, 8:05 AM EDT - 5 months ago

Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update

Aptevo Therapeutics Announces Closing of $2.75 Million Offering

Jul 1, 2024, 4:20 PM EDT - 7 months ago

Aptevo Therapeutics Announces Closing of $2.75 Million Offering

Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules

Jun 28, 2024, 9:20 AM EDT - 7 months ago

Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules

Aptevo Participating in the BIO International Convention

Jun 3, 2024, 8:05 AM EDT - 8 months ago

Aptevo Participating in the BIO International Convention

Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA

May 14, 2024, 8:05 AM EDT - 8 months ago

Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA

Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update

May 8, 2024, 8:05 AM EDT - 9 months ago

Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update

Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering

Apr 15, 2024, 4:05 PM EDT - 9 months ago

Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering

Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering

Apr 11, 2024, 8:00 AM EDT - 10 months ago

Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering

Aptevo Therapeutics Provides Pipeline Update

Apr 10, 2024, 9:00 AM EDT - 10 months ago

Aptevo Therapeutics Provides Pipeline Update

Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference

Mar 18, 2024, 6:00 AM EDT - 10 months ago

Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference

Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update

Mar 5, 2024, 8:05 AM EST - 11 months ago

Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update

Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan

Mar 4, 2024, 9:00 AM EST - 11 months ago

Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan

Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update

Nov 14, 2023, 8:05 AM EST - 1 year ago

Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update

Aptevo to Present at Bio-Europe Conference

Nov 1, 2023, 7:45 AM EDT - 1 year ago

Aptevo to Present at Bio-Europe Conference

Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update

Aug 10, 2023, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update

Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering

Aug 4, 2023, 6:40 PM EDT - 1 year ago

Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering

Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering

Aug 1, 2023, 10:15 PM EDT - 1 year ago

Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering

Aptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating the Bispecific APVO436 for AML

Jul 18, 2023, 8:05 AM EDT - 1 year ago

Aptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating the Bispecific APVO436 for AML

Aptevo Therapeutics Reports 1Q23 Financial Results and Provides Business Update

May 11, 2023, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Reports 1Q23 Financial Results and Provides Business Update

Aptevo Therapeutics Reports 2022 Financial Results and Provides Business Update

Mar 30, 2023, 7:45 AM EDT - 1 year ago

Aptevo Therapeutics Reports 2022 Financial Results and Provides Business Update

Aptevo Therapeutics Raises $9.6 Million in Non-Dilutive Funding

Mar 30, 2023, 7:30 AM EDT - 1 year ago

Aptevo Therapeutics Raises $9.6 Million in Non-Dilutive Funding

Aptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors

Jan 9, 2023, 8:05 AM EST - 2 years ago

Aptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors

Aptevo's stock rallies 107% after sharing preliminary data about experimental leukemia treatment

Dec 12, 2022, 8:37 AM EST - 2 years ago

Aptevo's stock rallies 107% after sharing preliminary data about experimental leukemia treatment

100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML)

Dec 12, 2022, 7:35 AM EST - 2 years ago

100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML)

Aptevo Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

Nov 10, 2022, 8:05 AM EST - 2 years ago

Aptevo Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

Aptevo Therapeutics Announces Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition

Nov 3, 2022, 9:06 AM EDT - 2 years ago

Aptevo Therapeutics Announces Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition

Aptevo Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

Aug 11, 2022, 8:05 AM EDT - 2 years ago

Aptevo Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia

Jun 9, 2022, 8:05 AM EDT - 2 years ago

Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia

Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

May 12, 2022, 8:05 AM EDT - 2 years ago

Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting

Apr 12, 2022, 8:05 AM EDT - 3 years ago

APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting

Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia

Mar 29, 2022, 8:05 AM EDT - 3 years ago

Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia

Why Did Aptevo Therapeutics Stock Jump 25% Today?

Mar 24, 2022, 2:59 PM EDT - 3 years ago

Why Did Aptevo Therapeutics Stock Jump 25% Today?

Aptevo Therapeutics Reports 2021 Financial Results and Provides Business Update

Mar 24, 2022, 8:05 AM EDT - 3 years ago

Aptevo Therapeutics Reports 2021 Financial Results and Provides Business Update

Why Are Aptevo Therapeutics Shares Trading Higher Today?

Feb 9, 2022, 2:28 PM EST - 3 years ago

Why Are Aptevo Therapeutics Shares Trading Higher Today?

Aptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE, Provides Company Update

Feb 9, 2022, 8:05 AM EST - 3 years ago

Aptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE, Provides Company Update

Aptevo Therapeutics' Board Chairman, Fuad El-Hibri, Announces Retirement, Effective April 1, 2022

Jan 21, 2022, 8:05 AM EST - 3 years ago

Aptevo Therapeutics' Board Chairman, Fuad El-Hibri, Announces Retirement, Effective April 1, 2022

Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal Nature Communication

Dec 15, 2021, 8:36 AM EST - 3 years ago

Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal Nature Communication